Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
A screen for combination therapies in BRAF/NRAS wild type... | ResearchHub
Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
A screen for combination therapies in BRAF/NRAS wild type melanoma identifies nilotinib plus MEK inhibitor as a synergistic combination
0
Authors
Marco Ranzani
44 more
Marco Ranzani
•
Mamunur Rashid
42 more
•
David Adams
Published
September 28, 2017
Paper
Conversation
0
Reviews
0
Bounties
0
Sign in to comment
Add a comment...
Best
Supporters
Support the authors with ResearchCoin
Tip RSC
Preprint Server
Topics
Biology
Cancer Oncology
Medicine
Internal Medicine
Nilotinib
Show all topics
DOI
10.1101/195354
License
cc-no
Supporters
Support the authors with ResearchCoin
Tip RSC
Preprint Server
Topics
Biology
Cancer Oncology
Medicine
Internal Medicine
Nilotinib
Show all topics
DOI
10.1101/195354
License
cc-no
